<table>
<thead>
<tr>
<th>Candidate SARS-CoV-2 Vaccine in Advanced Clinical Trials: Key Aspects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coronavirus Disease 2019 Vaccine Tracker</strong> (Lexi-Drugs)</td>
</tr>
</tbody>
</table>

**CLINICAL TRIALS:**

- [https://clinicaltrials.gov/ct2/show/NCT04324606](https://clinicaltrials.gov/ct2/show/NCT04324606)
- [https://clinicaltrials.gov/ct2/show/NCT04400838](https://clinicaltrials.gov/ct2/show/NCT04400838)
- [https://clinicaltrials.gov/ct2/show/NCT04444474](https://clinicaltrials.gov/ct2/show/NCT04444474)
- [https://clinicaltrials.gov/ct2/show/NCT04516746](https://clinicaltrials.gov/ct2/show/NCT04516746)
- [https://clinicaltrials.gov/ct2/show/NCT0283461](https://clinicaltrials.gov/ct2/show/NCT04516746)
- [https://clinicaltrials.gov/ct2/show/NCT04405076](https://clinicaltrials.gov/ct2/show/NCT04405076)
- [https://clinicaltrials.gov/ct2/show/NCT00056372](https://clinicaltrials.gov/ct2/show/NCT00056372)
- [https://clinicaltrials.gov/ct2/show/NCT04509947](https://clinicaltrials.gov/ct2/show/NCT04509947)
REFERENCES:


RESOURCE DOCUMENTS:


Food & Drug Administration, Fast Track & Similar Designations: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SARS-CoV-2 Vaccines: Evidence from Human Immunogenicity Studies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Title</strong></td>
<td>Vaccine Immunogenicity and Efficacy</td>
<td></td>
</tr>
<tr>
<td><strong>Authors</strong></td>
<td>Wang et al. 2021, UK-MRC/Oxford Vaccine Group</td>
<td></td>
</tr>
<tr>
<td><strong>Journal</strong></td>
<td>Nature Medicine</td>
<td></td>
</tr>
<tr>
<td><strong>Published</strong></td>
<td>2021</td>
<td></td>
</tr>
<tr>
<td><strong>DOI</strong></td>
<td>10.1038/s41591-021-01527-4</td>
<td></td>
</tr>
<tr>
<td><strong>Abstract</strong></td>
<td>This study evaluated the immunogenicity and efficacy of a two-dose regimen of the AstraZeneca COVID-19 vaccine (AZD1222) in a phase 3 randomized, double-blind, placebo-controlled trial conducted in the UK.</td>
<td></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td>The study enrolled 12,869 participants aged 18-65 years in two age groups:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18-55 years and 65-80 years. Within each age group, participants were randomized 2:1 to receive two doses of the vaccine or placebo at 4-12 weeks.</td>
<td></td>
</tr>
<tr>
<td><strong>Primary Endpoint</strong></td>
<td>The primary endpoint was the frequency of COVID-19 cases among participants who received the vaccine compared to placebo.</td>
<td></td>
</tr>
<tr>
<td><strong>Results</strong></td>
<td>The vaccine was highly immunogenic, with a median seroconversion rate of 100% at 28 days post-dose 1.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The vaccine was also highly efficacious, with a 70% reduction in the risk of COVID-19 infection.</td>
<td></td>
</tr>
<tr>
<td><strong>Conclusion</strong></td>
<td>The AstraZeneca COVID-19 vaccine is highly immunogenic and efficacious in preventing COVID-19 infection.</td>
<td></td>
</tr>
</tbody>
</table>
REFERENCES:


Applies to

Coronavirus Vaccine; COVID-19; COVID-19 Vaccine Tracker; COVID19; COVID19 Vaccine Tracker; SARS-CoV-2 Vaccine

Last Updated 2/2/21

© 2020 UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.